Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report

West Indian Med J. 2013;62(4):377-9. doi: 10.7727/wimj.2011.193.

Abstract

Sustained increase of serum creatine phosphokinase (CPK) concentrations and muscle abnormalities have been reported in patients taking raltegravir (RAL). In this report, we describe a case of sustained and asymptomatic increase of serum CPK concentrations associated with raltegravir, zidovudine, and lamivudine in an HIV-1 experienced patient with intolerance to protease inhibitor, abacavir and penicillin during 32 weeks of continuous drug monitoring.

Publication types

  • Case Reports

MeSH terms

  • Anti-HIV Agents / adverse effects*
  • Antiretroviral Therapy, Highly Active
  • Creatine Kinase / blood
  • HIV Infections / drug therapy*
  • HIV-1*
  • Humans
  • Lamivudine / therapeutic use*
  • Male
  • Middle Aged
  • Muscle Weakness / chemically induced*
  • Myalgia / chemically induced*
  • Pyrrolidinones / adverse effects*
  • Raltegravir Potassium
  • Zidovudine / therapeutic use*

Substances

  • Anti-HIV Agents
  • Pyrrolidinones
  • Lamivudine
  • Raltegravir Potassium
  • Zidovudine
  • Creatine Kinase